DexCom’s (DXCM) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of DexCom (NASDAQ:DXCM) in a report released on Friday,Benzinga reports. The firm currently has a $85.00 target price on the medical device company’s stock.

Several other analysts have also recently commented on the company. UBS Group lowered their target price on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Citigroup reissued a “buy” rating and issued a $77.00 price target (up previously from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Evercore assumed coverage on DexCom in a report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Friday, October 31st. Finally, Stifel Nicolaus initiated coverage on shares of DexCom in a research note on Tuesday, October 21st. They set a “buy” rating and a $85.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $85.27.

DexCom Stock Up 7.6%

Shares of DexCom stock opened at $70.02 on Friday. The stock has a market capitalization of $26.95 billion, a price-to-earnings ratio of 33.34, a PEG ratio of 1.25 and a beta of 1.49. DexCom has a twelve month low of $54.11 and a twelve month high of $93.25. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The business’s 50 day simple moving average is $69.03 and its 200-day simple moving average is $69.47.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s revenue was up 13.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.45 EPS. Equities research analysts forecast that DexCom will post 2.03 earnings per share for the current year.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the business. Andra AP fonden bought a new stake in DexCom during the second quarter worth approximately $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom during the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. boosted its stake in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares in the last quarter. Financial Consulate Inc. acquired a new position in shares of DexCom in the 3rd quarter worth $29,000. Finally, CVA Family Office LLC raised its position in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat expectations: DexCom reported $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY); management reiterated 2026 guidance, supporting near-term outlook. Dexcom beats quarterly estimates
• Positive Sentiment: G7 15‑day sensor rollout and margin gains cited as growth drivers — management pointed to product adoption and improving margins as catalysts for revenue and profitability expansion. G7 rollout drives growth
• Positive Sentiment: Mizuho raised its price target to $90 (outperform), signaling confidence in longer‑term upside and helping buy‑side sentiment. Mizuho price target raise
• Positive Sentiment: BTIG reaffirmed a Buy rating with an $85 target, adding to analyst support that underpins the rally. BTIG reaffirmation
• Positive Sentiment: Product/AI initiative — the Stelo AI upgrade aims to deepen consumer metabolic-health engagement, which could expand recurring usage and ARPU over time. Stelo AI upgrade
• Neutral Sentiment: Analyst activity is mixed overall: several firms maintained or raised targets while at least one adjusted its price target (see below). This creates both support and some variability in near-term expectations. Wall Street analyst targets
• Neutral Sentiment: Trading indicators: intraday volume is notably above the stock’s average, which amplifies price moves but can increase short-term volatility. (Background market data)
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous zero/NaN values and a 0.0 days‑to‑cover figure — the data appears unreliable and should be treated cautiously by traders monitoring short activity.
• Negative Sentiment: Wells Fargo trimmed its price target from $93 to $85 despite keeping an Overweight rating, a modest negative signal that reduces the high‑end analyst consensus. Wells Fargo target cut

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.